MX2012013735A - Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos. - Google Patents

Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.

Info

Publication number
MX2012013735A
MX2012013735A MX2012013735A MX2012013735A MX2012013735A MX 2012013735 A MX2012013735 A MX 2012013735A MX 2012013735 A MX2012013735 A MX 2012013735A MX 2012013735 A MX2012013735 A MX 2012013735A MX 2012013735 A MX2012013735 A MX 2012013735A
Authority
MX
Mexico
Prior art keywords
neuregulin
polypeptides
isoforms
relates
present
Prior art date
Application number
MX2012013735A
Other languages
English (en)
Inventor
Thierry Baussant
Daniel Bach
Andre Schrattenholz
Original Assignee
Mind Nrg Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mind Nrg Sa filed Critical Mind Nrg Sa
Publication of MX2012013735A publication Critical patent/MX2012013735A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

La presente invención se refiere a nuevos usos terapéuticos y diagnósticos de isoformas y polipéptidos de neuregulina 1 soluble, en particular para trastornos neurológicos.
MX2012013735A 2010-05-28 2011-05-27 Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos. MX2012013735A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34945110P 2010-05-28 2010-05-28
PCT/EP2011/058769 WO2011147981A2 (en) 2010-05-28 2011-05-27 Neuregulin isoforms, neuregulin polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2012013735A true MX2012013735A (es) 2013-04-29

Family

ID=44343932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013735A MX2012013735A (es) 2010-05-28 2011-05-27 Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.

Country Status (12)

Country Link
US (2) US20130072437A1 (es)
EP (1) EP2575862A2 (es)
JP (1) JP2013529911A (es)
KR (1) KR20130113962A (es)
CN (1) CN103118698A (es)
AU (1) AU2011257192A1 (es)
BR (1) BR112012030331A2 (es)
CA (1) CA2800766A1 (es)
IL (1) IL222966A0 (es)
MX (1) MX2012013735A (es)
RU (1) RU2012157572A (es)
WO (1) WO2011147981A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
BR112016016153A2 (pt) 2014-01-13 2017-12-12 Berg Llc composições de enolase 1 (eno1) e usos das mesmas
US10557859B2 (en) 2015-05-05 2020-02-11 The Regents Of The University Of California Astrocyte traumatome and neurotrauma biomarkers
CN115919889A (zh) 2015-12-22 2023-04-07 雀巢产品有限公司 用于治疗肌肉减少症和虚弱的方法
EP3445386B1 (en) * 2016-04-19 2020-08-26 Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI) Neuregulin for the treatment and/or prevention of tumors of the nervous system
US10199266B2 (en) 2016-12-26 2019-02-05 Intel Corporation Integrated circuit interconnect structure having metal oxide adhesive layer
US11709168B2 (en) 2017-05-23 2023-07-25 Brainbox Solutions, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
AU2018272294B2 (en) 2017-05-24 2024-05-23 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
CN108421032A (zh) * 2018-05-14 2018-08-21 南方医科大学 神经调节素1在制备治疗***抑郁症药物中的应用
CN112512573A (zh) * 2018-05-23 2021-03-16 百提威生技股份有限公司 双特异性t细胞衔接蛋白及其用途
CN110946991A (zh) * 2018-09-27 2020-04-03 广州中医药大学(广州中医药研究院) 神经调节蛋白1的应用
CN112438990A (zh) * 2019-08-29 2021-03-05 鲁南制药集团股份有限公司 肝素、或其衍生物、或其可药用盐的新用途
CN110721307A (zh) * 2019-12-03 2020-01-24 广州中医药大学(广州中医药研究院) 神经调节蛋白1在制备增强trpc6通道活性产品中的应用
CN112481246B (zh) * 2020-12-16 2022-03-29 熊猫乳品集团股份有限公司 一种生物活性多肽fspankkltpkky及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285531B1 (en) * 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
WO1994028133A1 (en) * 1993-05-21 1994-12-08 Amgen Inc. Recombinant neu differentiation factors
DE69840699D1 (de) * 1997-02-10 2009-05-14 Genentech Inc Heregulin varianten
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2003012045A2 (en) * 2001-07-31 2003-02-13 Wayne State University Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US7994123B2 (en) * 2004-07-09 2011-08-09 Wayne State University Hybrid proteins with ErbB4 extracellular domain and neuregulin heparin-binding domain for targeting
AU2005263577C1 (en) 2004-07-16 2010-08-26 Proteosys Ag Muscarinic antagonists with PARP and SiR modulating activity as cytoprotective agents
EP1890722A2 (en) * 2005-05-27 2008-02-27 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
CN104645315A (zh) * 2008-02-29 2015-05-27 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
WO2009137837A2 (en) * 2008-05-09 2009-11-12 The Regents Of The University Of California Neuregulin/erbb signaling and integrin
US9498515B2 (en) * 2008-08-15 2016-11-22 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following CNS neurological injury

Also Published As

Publication number Publication date
US20150080302A1 (en) 2015-03-19
KR20130113962A (ko) 2013-10-16
IL222966A0 (en) 2013-02-03
RU2012157572A (ru) 2014-07-10
CN103118698A (zh) 2013-05-22
WO2011147981A2 (en) 2011-12-01
CA2800766A1 (en) 2011-12-01
EP2575862A2 (en) 2013-04-10
JP2013529911A (ja) 2013-07-25
US20130072437A1 (en) 2013-03-21
BR112012030331A2 (pt) 2017-06-20
AU2011257192A1 (en) 2013-01-10
WO2011147981A3 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
MX2012013735A (es) Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
PH12015501806A1 (en) Novel benzopyran kinase modulators
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2013010342A (es) Uso de dosis bajas de il-2 para tratar transtornos inflamatorios o relacionados con la autoinmunidad.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
IN2012DN02469A (es)
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
MX2013008702A (es) Composiciones que contienen anticuerpos glicosilados y sus usos.
WO2012058241A3 (en) Methods and compositions for ameliorating pancreatic cancer
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
SG179203A1 (en) Novel arylated camphenes, processes for their preparation and uses thereof
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
SA515360377B1 (ar) نظائر خيمرية من سوماتوستاتين- دوبامين
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2012085608A3 (en) Use of trifluoro phthalimides for the treatment of cancerous diseases
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.
TN2010000463A1 (en) Compositions and methods for preparing and using same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal